CMS Coverage Policy, IT Programs Foster Information Transfer – Tunis
This article was originally published in The Gray Sheet
Executive Summary
CMS input during a company's clinical research design process could set the stage for more effective information transfer as the technology moves past the regulatory process into clinical practice, CMS Acting Chief Medical Officer Sean Tunis suggested at an "evidence-based innovations" healthcare conference Jan. 27 in Washington, D.C
You may also be interested in...
FDA Will Play Supporting Role, Not Preside Over Cost-Effectiveness Criteria
The growing call for greater federal cost-effectiveness evaluation of new medical technologies will not alter FDA's primary focus on risk-benefit analysis
Device Center To Add Program For Joint Planning Of PMA Submissions
The Center for Devices and Radiological Health is planning to offer a new type of meeting in which sponsors and FDA reviewers agree on content and format of a premarket application submission
Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Gel
Theradaptive, which makes a device-biologic combination product to help speed bone healing, recently got authorization to start human trials from the US FDA. Medtech Insight spoke to CEO Luis Alvarez about the company’s past, present and future.